Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Berruti

Showing results (81-90 of 150) with videos related to

Pageof 15
Sort By:
Journal of Endocrinological Investigation|December 24, 2015
Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?F Porpiglia, C Fiori, F C Daffara, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1997
Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable diseaseA Bottini, A Berruti, M Tampellini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2006
Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?M Ardine, D Generali, M Donadio, et al.
ESMO Open|February 26, 2023
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studiesV Amoroso, F Gallo, A Alberti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2020
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upM Fassnacht, G Assie, E Baudin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 2022
Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]M Fassnacht, G Assie, E Baudin, et al.
Anticancer Research|September 1, 1996
Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumoursA Bottini, A Berruti, A Bersiga, et al.
European Urology|January 3, 2006
Reassessing the current TNM lymph node staging for renal cell carcinomaCarlo Terrone, C Cracco, F Porpiglia, et al.
ESMO Open|June 20, 2024
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategiesM C Cursano, A A Valsecchi, F Pantano, et al.
European Journal of Pain (London, England)|November 6, 2014
Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough painR Sperlinga, S Campagna, A Berruti, et al.
Pageof 15

Showing results (81-90 of 150) with videos related to

Sort By:
Pageof 15
Journal of Endocrinological Investigation|December 24, 2015
Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?F Porpiglia, C Fiori, F C Daffara, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1997
Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable diseaseA Bottini, A Berruti, M Tampellini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2006
Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?M Ardine, D Generali, M Donadio, et al.
ESMO Open|February 26, 2023
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studiesV Amoroso, F Gallo, A Alberti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2020
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upM Fassnacht, G Assie, E Baudin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 2022
Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]M Fassnacht, G Assie, E Baudin, et al.
Anticancer Research|September 1, 1996
Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumoursA Bottini, A Berruti, A Bersiga, et al.
European Urology|January 3, 2006
Reassessing the current TNM lymph node staging for renal cell carcinomaCarlo Terrone, C Cracco, F Porpiglia, et al.
ESMO Open|June 20, 2024
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategiesM C Cursano, A A Valsecchi, F Pantano, et al.
European Journal of Pain (London, England)|November 6, 2014
Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough painR Sperlinga, S Campagna, A Berruti, et al.
Pageof 15